IP Library Granted Patent US 10,959,413
Granted Patent B2
US 10,959,413 · App. 15/766,551 · Granted Mar 30, 2021

Multiplexed genome editing

Inventors: George M. Church (Brookline, MA); Luhan Yang (Somerville, MA); Marc Guell (Barcelona, ES)
Assignee: President and Fellows of Harvard College
A01K67/0275A01K67/0273A01K67/0276C12N7/00C12N9/22C12N15/11C12N15/1132C12N15/63C12N15/85C12N15/8509C12N15/907A01K2207/05A01K2207/10A01K2227/108A01K2267/025C07H21/02C07H21/04C12N2310/20C12N2740/10062C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,959,413
App. No.
15/766,551
Granted
Mar 30, 2021
Kind
B2
Abstract

A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.

Claims (10)

1. A method of inactivating expression of at least 20% of the copies of an endogenous retroviral target gene in a cell comprising multiple copies of the gene, comprising:

(a) introducing into the cell (i) one or more guide ribonucleic acid (gRNA) sequences that comprise a portion that is complementary to a portion of the endogenous retroviral target gene, and (ii) a nucleic acid sequence that encodes a Cas protein; and

(b) maintaining the cells under conditions in which (i) the Cas protein is expressed, (ii) the Cas protein and gRNAs form co-localization complexes with a plurality of the copies of the endogenous retroviral target gene, and (iii) the Cas protein cuts at least 20% of the copies of the endogenous retroviral target gene, thereby inactivating expression of said copies.

2. The method of claim 1 , wherein the cell is a stem cell, zygote, or a germ line cell.

3. The method of claim 1 , wherein the cell is a porcine cell.

4. The method of claim 1 , wherein the endogenous retroviral target gene is a porcine endogenous retrovirus (PERV) gene.

5. The method of claim 4 , wherein the PERV gene comprises a pol gene.

6. The method of claim 5 , wherein all copies of the pol gene in the cell are inactivated.

7. The method of claim 1 , wherein the Cas protein is a Cas9.

8. The method of claim 1 , wherein the one or more gRNA sequences are about 10 to about 1000 nucleotides.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2018
From: CHURCH, GEORGE M.; GUELL, MARC; YANG, LUHAN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 047802/0368 →
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046545/0555 →
Continuity (2)
Provisional Application 62239239 · Oct 8, 2015
Related Publication 20180288983A1 · Oct 11, 2018
Cited By (4)
US 12,612,643 US 12,630,838 US 12,637,690 US 12,649,928